Oxcarbazepine is a sodium channel blocker. Oxcarbazepine significantly inhibits glioblastoma cell growth and induces apoptosis or G2/M arrest in glioblastoma cell lines. Anti-cancer and anticonvulsant effects.
性状
Solid
IC50 & Target[1][2]
Sodium Channel.
体外研究(In Vitro)
Oxcarbazepine significantly inhibits glioblastoma cell growth and reaches IC50 at therapeutic concentrations. The IC50s of Oxcarbazepine screened with the U87 and T98 cell lines are 12.35 and 9.45 μg/mL,respectively.
Medlife has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Viability Assay
Cell Line:
Human glioma cell lines U-87 MG and T98G
Concentration:
2.5, 5, 10, 20, and 40 μg/mL
Incubation Time:
72 hours
Result:
The growth inhibition for the T98G cell line for each concentration was 17.7±4.1% (2.5 μg/mL), 21.1±3.6% (5 μg/mL), 53.6±14.2% (10 μg/mL), 82.2±2.3% (20 μg/mL), and 85.0±2.3% (40 μg/mL).
The growth inhibition for U-87 MG cell line for each concentration was ?1.7±5.1% (0.008 μg/mL), 5.3±2.4% (0.08 μg/mL), 3.5±7.4% (0.8 μg/mL), 0.3±9.2% (16 μg/mL), and ?4.2±9.6% (40 μg/mL).
体内研究(In Vivo)
Oxcarbazepine protectes mice and rats against generalized tonic-clonic seizures induced by electroshock with ED50 values between 13.5 and 20.5 mg/kg p.o. No tolerance toward this anticonvulsant effect is observed when rats are treated with Oxcarbazepine daily for 4 weeks.
Medlife has not independently confirmed the accuracy of these methods. They are for reference only.